Form 4: Firefly Neuroscience Director Boosts Equity Stake

Stella Vnook, a Director at Firefly Neuroscience, Inc., was granted 49,262 deferred stock units under the company's 2024 Long-Term Incentive Plan.

Summary

• Stella Vnook, a Director of Firefly Neuroscience, Inc. (AIFF), was granted 49,262 deferred stock units (DSUs) on October 28, 2025.
• The DSUs were granted under the Issuer's 2024 Long-Term Incentive Plan.
• Each DSU represents a contingent right to receive one share of the Issuer's common stock.
• The DSUs will vest quarterly over a twelve-month period.
• Following this transaction, Stella Vnook beneficially owns 65,929 derivative securities.

Sentiment

Score: 7

Explanation: The grant of equity to a director is a positive signal for corporate governance and alignment of interests, though it's a routine event and not indicative of extraordinary performance.

Positives

• The grant of deferred stock units aligns the interests of Director Stella Vnook with those of the shareholders, as her compensation is tied to the company's future stock performance.
• The transaction is part of a structured 2024 Long-Term Incentive Plan, indicating a formal approach to executive and director compensation.

Negatives

• The conversion of DSUs into common stock will result in a minor dilution of existing shareholder equity, which is a standard aspect of equity compensation plans.

Future Outlook

The deferred stock units granted to Director Stella Vnook are scheduled to vest quarterly over a twelve-month period, indicating future share issuances contingent on continued service.

Industry Context

Equity grants to directors are a common practice across industries, particularly in the biotechnology and neuroscience sectors, to attract and retain talent and align leadership interests with long-term company performance.

Comparison to Industry Standards

• The grant of deferred stock units as part of a long-term incentive plan is a standard compensation practice for directors in publicly traded companies, comparable to similar plans at companies like Biogen Inc. or Eli Lilly and Company, which frequently use equity awards to incentivize their leadership.
• The vesting schedule of quarterly over twelve months is a typical short-to-medium term vesting period for such awards, ensuring continued engagement and performance from the director.

Corporate Governance

Related Party Transactions

• The grant of deferred stock units to Stella Vnook, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential minor dilution upon DSU conversion, but improved alignment of director's interests with shareholder value.
• Director (Stella Vnook): Receives equity-based compensation, linking personal wealth to company performance.

Next Steps

• The deferred stock units will vest quarterly over the next twelve months, leading to the eventual issuance of common stock to Stella Vnook.

Key Dates

Keywords

Firefly Neuroscience, AIFF, Stella Vnook, Deferred Stock Units, DSU, Equity Compensation, Director Compensation, SEC Form 4, Insider Transaction, Long-Term Incentive Plan